公开(公告)号：AU2013291440A1

公开(公告)日：2015-02-12

申请号：AU2013291440

申请日：2013-07-19

Applicant: NIPPON SODA CO ,  SHIZUOKA PREFECTURE

Inventor： KAGEYAMA CHIZUKO ,  IYOZUMI HIROYUKI ,  NUKUI HIDEKI ,  KATO KIMIHIKO ,  MANNEN JUNYA ,  TOMIDA KAZUYUKI ,  SANO SHINSUKE ,  KATO HIDEKI ,  MAKITA SATORU ,  MIZUNO TOSHIO

IPC: A01N43/08 ,  A01G7/06 ,  A01N25/32 ,  A01N43/16 ,  A01N43/40 ,  A01N43/54 ,  A01P21/00

Abstract: The present invention pertains to a method for providing plants with resistance to stress, wherein at least one substance (A) selected from a group comprising a compound represented by formula (I) etc. and a salt thereof is applied to plants. The method reduces the harmful effects of pesticides on plants by providing the plants with resistance to stress. [In formula (I): R

公开(公告)号：NZ602099A

公开(公告)日：2014-06-27

申请号：NZ60209909

申请日：2009-07-10

Applicant: PHARMA IP GENERAL INC ASS ,  PHARMA DESIGN INC ,  SHIZUOKA PREFECTURE ,  KUMAMOTO HEALTH SCIENCE UNIVERSITY ,  YAKULT HONSHA KK

Inventor： ASAI AKIRA ,  MATSUNO KENJI ,  OGO NAOHISA ,  YOKOTAGAWA TAKANE ,  TAKAHASHI OSAMU ,  AKIYAMA YASUTO ,  ASHIZAWA TADASHI ,  OKAWARA TADASHI

IPC: C07D417/14 ,  A61K31/4196 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4709 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D215/50 ,  C07D215/52 ,  C07D249/08 ,  C07D249/14 ,  C07D271/10 ,  C07D271/113 ,  C07D285/12 ,  C07D285/135 ,  C07D401/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: Disclosed is the use of N-[1,3,4-oxadiazol-2-yl]-2-phenyl-4-quinolinecarboxamide, N-[1,3,4-thiadiazol-2-yl]-2-phenyl-4-quinolinecarboxamide and N-[1,3,4-triazol-2-yl]-2-phenyl-4-quinolinecarboxamide derivatives as represented by the general formula (I) in the manufacture of a medicament for the treatment and/or prevention of cancer by inhibition of STAT3, wherein R2 is hydrogen or methyl; R3 is a substituted or unsubstituted aryl group; W is a single bond or an unsubstituted alkylene group; X represents an oxygen atom, a sulphur atom, or NR34; and wherein the remaining substituents are as defined herein. Representative compounds of formula (I) include N-[5-(2-furyl)-1,3,4-oxadiazol-2-yl]-2-phenyl-4-quinolinecarboxamide, N-[5-(2-furyl)-1,3,4-oxadiazol-2-yl]-6-chloro-2-thienyl-4-quinolinecarboxamide, N-[5-(2-furyl)-1,3,4-oxadiazol-2-yl]-2-(4-(tert-butoxycarbonyl)phenyl)-4-quinolinecarboxamide, N-[5-(2-furyl)-1,3,4-oxadiazol-2-yl]-2-(1,3-benzodioxol-5-yl)-4-quinolinecarboxamide and N-[5-(2-furyl)-1,3,4-oxadiazol-2-yl]-6-bromo-2-(phenyl)-4-quinolinecarboxamide.

公开(公告)号：CA2879519A1

公开(公告)日：2014-01-23

申请号：CA2879519

申请日：2013-07-19

Applicant: NIPPON SODA CO ,  SHIZUOKA PREFECTURE

Inventor： KAGEYAMA CHIZUKO ,  IYOZUMI HIROYUKI ,  NUKUI HIDEKI ,  KATO KIMIHIKO ,  MANNEN JUNYA ,  TOMIDA KAZUYUKI ,  SANO SHINSUKE ,  KATO HIDEKI ,  MAKITA SATORU ,  MIZUNO TOSHIO

IPC: A01N43/08 ,  A01G7/06 ,  A01N25/32 ,  A01N43/16 ,  A01N43/40 ,  A01N43/54 ,  A01P21/00

Abstract: The present invention pertains to a method for providing plants with resistance to stress, wherein at least one substance (A) selected from a group comprising a compound represented by formula (I) etc. and a salt thereof is applied to plants. The method reduces the harmful effects of pesticides on plants by providing the plants with resistance to stress. [In formula (I): R1 to R4 each independently represent a hydrogen atom, -SO3H, -PO3H2, a glycosyl group or -COR11; and R11 represents an unsubstituted or substituted alkyl group with 1 to 30 carbons, or an unsubstituted or substituted alkenyl group with 2 to 30 carbons.]

公开(公告)号：CA2750212A1

公开(公告)日：2010-07-29

申请号：CA2750212

申请日：2010-01-22

Applicant: SHIZUOKA PREFECTURE PUBLIC UNIVERSITY CORP

Inventor： KAINUMA YASUKO

IPC: A23L7/10 ,  A21D13/04 ,  A23L7/196

Abstract: Disclosed are a food material using rice as a starting material, which is sufficiently available as a substitute from the standpoint of cost at the commercial level, a processed food using the same, and a method for the production thereof. Rice grains are soaked in water to give a liquid with rice grains soaked therein and the rice grains are allowed to absorb water in this state. The whole liquid with rice grains soaked therein is fed into a mill and milled therein. Thus, water-absorbed fine rice grains are obtained. These water-absorbed fine rice grains are characterized by being a rice paste wherein free water occupies the space among the fine rice grains. Thus, the fine rice grains in the rice paste can be miniaturized. Owing to the action of the free water in the course of milling, heat denaturation of rice components can be prevented. The fine rice grains can be maintained in the water-absorbed state, which makes it possible to avoid damage of the fine rice grains (simple starch grains) caused by drying. Moreover, the free water improves the compatibility of the rice paste with a kneaded matter comprising a cereal flour of a different kind or other materials, which facilitates the mixing of these materials.

公开(公告)号：AU2008356312A1

公开(公告)日：2009-11-19

申请号：AU2008356312

申请日：2008-08-29

Applicant: TAIHO PHARMACEUTICAL CO LTD ,  SHIZUOKA PREFECTURE

Inventor： PARK SUNG HWA

IPC: A61K31/513 ,  A61K31/44 ,  A61K31/519 ,  A61K31/53 ,  A61K33/24 ,  A61P35/00

Abstract: Disclosed are an antitumor preparation comprising a combination of (1) a combination drug of tegafur/gimeracil/oteracil potassium, (2) at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof, and (3) cis-oxalate(1R,2R-diaminocyclohexane)platinum(II) ; a kit comprising a combination of pharmaceutical compositions for treating cancer in a mammal, comprising: (a) a combination drug of tegafur/gimeracil/oteracil potassium in a therapeutically effective amount; (b) a composition containing at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof in an amount effective for enhancing antitumor effects, and (c) a composition containing cis-oxalate(1R,2R-diaminocyclohexane)platinum(II) in an amount effective for enhancing antitumor effects; and a method for treating cancer.

公开(公告)号：HK1113316A1

公开(公告)日：2008-10-03

申请号：HK08103552

申请日：2008-03-31

Applicant: ASAMA KASEI KK ,  SHIZUOKA PREFECTURE

Inventor： YAJIMA MIZUO ,  IWATSUKI SATOSHI ,  SHIONOYA HIROSHI ,  TERADO KUNIAKI ,  AKAMATSU HIROHISA ,  SUZUKI SHUUKA ,  KATOH MASAMICHI

IPC: A23C20060101 ,  A23G20060101 ,  A23J20060101 ,  A61K20060101 ,  A61K35/20 ,  A61K39/00 ,  A61P20060101

Abstract: There is provided a composition comprising an antibacterial-endotoxin antibody, for use in the treatment of rheumatoid arthritis, a whey protein food comprising whey protein and one or more indigestible saccharides, an antibody-containing food comprising an antibody contained in whey protein and one or more bacteria selected from lactobacilli and bifidobacteria, and a protein composition excellent in water dispersibility, comprising a powdered or granulated whey protein and a powdery unsolidifiable and insoluble substance.

公开(公告)号：CA3029926C

公开(公告)日：2023-01-03

申请号：CA3029926

申请日：2016-07-25

Applicant: SHIZUOKA PREFECTURE

Inventor： MOCHIZUKI TOHRU ,  OHSHIMA KEIICHI ,  HATAKEYAMA KEIICHI ,  YAMAGUCHI KEN ,  NAKAO KANAKO

IPC: G01N33/574

Abstract: An object of the present invention is to provide a method for collecting highly accurate data for diagnosis, useful in diagnosing the presence or absence of extrahepatic bile duct carcinoma, intrahepatic bile duct carcinoma, or gallbladder carcinoma, and a kit for diagnosis. When the concentration of CEACAM1 in a blood sample collected from a test subject is detected using a kit for diagnosis comprising an antibody specifically binding to CEACAM1 or a labeled product thereof, or the like and the CEACAM1 concentration is higher than the concentration of CEACAM1 in a blood sample derived from a non-carcinoma control subject or higher than a certain threshold value (cutoff value), data can be collected for diagnosing the test subject as having a high possibility of having extrahepatic bile duct carcinoma, intrahepatic bile duct carcinoma, or gallbladder carcinoma.

公开(公告)号：CA2785679C

公开(公告)日：2017-12-12

申请号：CA2785679

申请日：2010-12-28

Applicant: GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION ,  PHARMA DESIGN INC ,  SHIZUOKA PREFECTURE ,  KUMAMOTO HEALTH SCIENCE UNIV ,  YAKULT HONSHA KK

Inventor： ASAI AKIRA ,  MATSUNO KENJI ,  OGO NAOHISA ,  TAKAHASHI OSAMU ,  MASUDA YOSHIAKI ,  MUROYA AYUMU ,  AKIYAMA YASUTO ,  ASHIZAWA TADASHI ,  OKAWARA TADASHI

IPC: C07D413/04 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/55 ,  A61P35/00 ,  A61P43/00 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04

Abstract: Disclosed is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Specifically disclosed is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In the formula, Ar represents a furyl group or the like; R1 represents a hydrogen atom or the like; and -X-Y represents a diaryl group such as a biphenyl group.)

公开(公告)号：PL2520575T3

公开(公告)日：2017-05-31

申请号：PL10841060

申请日：2010-12-28

Applicant: GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION ,  SHIZUOKA PREFECTURE ,  KUMAMOTO HEALTH SCIENCE UNIV ,  YAKULT HONSHA KK

Inventor： ASAI AKIRA ,  MATSUNO KENJI ,  OGO NAOHISA ,  TAKAHASHI OSAMU ,  MASUDA YOSHIAKI ,  MUROYA AYUMU ,  AKIYAMA YASUTO ,  ASHIZAWA TADASHI ,  OKAWARA TADASHI

IPC: C07D413/04 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/55 ,  A61P35/00 ,  A61P43/00 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04

公开(公告)号：CA2729988C

公开(公告)日：2016-09-13

申请号：CA2729988

申请日：2009-07-10

Applicant: PHARMA IP GENERAL INCORPORATED ASS ,  PHARMA DESIGN INC ,  SHIZUOKA PREFECTURE ,  KUMAMOTO HEALTH SCIENCE UNIV ,  YAKULT HONSHA KK

Inventor： ASAI AKIRA ,  MATSUNO KENJI ,  OGO NAOHISA ,  YOKOTAGAWA TAKANE ,  TAKAHASHI OSAMU ,  AKIYAMA YASUTO ,  ASHIZAWA TADASHI ,  OKAWARA TADASHI

IPC: C07D413/14 ,  A61K31/4709 ,  A61P35/00 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention provides a STAT3 inhibitor containing as an active ingredient, a quinolinecarboxamide derivative represented by the formula (I) (in the formula, W represents a bond or an alkylene chain; X represents O, S, or NR34; and R1 to R8 and R34 each represent H, halogen, alkyl, phenyl, furyl, thienyl, or the like.), or a pharmacologically acceptable salt thereof. 1